Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 17/20 | 0.85 |
| ▸ | KDR | P35968 | 16/20 | 0.85 |
| ▸ | TEK | Q02763 | 14/20 | 0.85 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
| ▸ | FES | P07332 | 1/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.52 |
| ▸ | FGR | P09769 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | CSK | P41240 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974775 | 0.92 | LCK (1.00) | LCKKDRTEKBTKKIT | |
| SCHEMBL4714839 | 0.85 | KDR (0.65) | LCKKDRTEKPDGFRBKIT | |
| SCHEMBL14108027 | 0.84 | LCK (0.67) | LCKKDRTEKBTKKIT | |
| SCHEMBL22384750 | 0.83 | KDR (0.65) | LCKKDRTEKPDGFRBBTK | |
| SCHEMBL4715351 | 0.83 | LCK (0.78) | LCKKDRTEKKITJAK3 | |
| SCHEMBL13202026 | 0.82 | LCK (0.80) | LCKKDRTEKBTKKIT | |
| SCHEMBL22683128 | 0.82 | LCK (1.00) | LCKKDRTEKBTKKIT | |
| SCHEMBL4715363 | 0.82 | LCK (0.67) | LCKKDRTEKMAPK14 | |
| SCHEMBL13349323 | 0.80 | LCK (0.78) | LCKKDRTEKBTKKIT | |
| SCHEMBL4041879 | 0.78 | LCK (0.71) | LCKKDRTEKKITJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| CN-101198602-A | Saminopyrimidine derivates with tIE2 inhibiting activity | ASTRAZENECA AB (SE) | 2008-06-11 | — | — | CN | disclosed |
| EP-1893605-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006103449-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | TIE1, TEK, FLT1 | LCK 902/4885KDR 4/4885TEK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.